Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting : the Nordic experience. The Nordic Antiemetic Trial Group
(1995) In Anti-Cancer Drugs 6(Suppl 1). p.6-31- Abstract
To evaluate the efficacy and safety of Navoban (tropisetron) three different Nordic multicentre trials were conducted during the period 1988-92. In all, 1050 patients were recruited from 15 centres. In the first study, Navoban monotherapy was compared with a high-dose metoclopramide cocktail. In the second, Navoban +/- dexamethasone was evaluated for those patients not fully protected by Navoban alone. In the third trial, Navoban was evaluated for various chemotherapy regimens, for long-term efficacy, and for various risk groups of patients. Spontaneous intercycle variations were also evaluated. Navoban was found to be as effective as the antiemetic cocktail but with a more favourable spectrum of side effects and a simpler schedule of... (More)
To evaluate the efficacy and safety of Navoban (tropisetron) three different Nordic multicentre trials were conducted during the period 1988-92. In all, 1050 patients were recruited from 15 centres. In the first study, Navoban monotherapy was compared with a high-dose metoclopramide cocktail. In the second, Navoban +/- dexamethasone was evaluated for those patients not fully protected by Navoban alone. In the third trial, Navoban was evaluated for various chemotherapy regimens, for long-term efficacy, and for various risk groups of patients. Spontaneous intercycle variations were also evaluated. Navoban was found to be as effective as the antiemetic cocktail but with a more favourable spectrum of side effects and a simpler schedule of administration. Navoban was more effective during the acute than the delayed phase. Addition of dexamethasone significantly improved prevention of both acute and delayed emesis. Long term efficacy seemed to be stable up to 10 cycles of chemotherapy. Patients treated with noncisplatin regimens showed significantly higher protection rates than patients treated with cisplatin. Various cancer diagnoses and cytostatic agents were also evaluated. Gender and age were important risk factors. Navoban was found to be an efficacious antiemetic agent, especially regarding acute nausea and vomiting. Addition of a corticosteroid significantly improved the effect during highly emetogenic chemotherapy. The role of Navoban for delayed emesis must be evaluated in future trials. The two most common side effects were headache and constipation. Overall, Navoban was well tolerated and patient compliance with the drug was high.
(Less)
- author
- Sorbe, B G ; Högberg, T LU ; Glimelius, B ; Schmidt, M ; Wernstedt, L ; Andersson, H ; Hansen, O LU ; Sørensen, B T and Räisänen, I
- organization
- publishing date
- 1995-02
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Antiemetics/therapeutic use, Antineoplastic Agents/adverse effects, Dexamethasone/therapeutic use, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Indoles/therapeutic use, Male, Nausea/chemically induced, Neoplasms/drug therapy, Risk Factors, Sweden, Tropisetron, Vomiting/chemically induced
- in
- Anti-Cancer Drugs
- volume
- 6
- issue
- Suppl 1
- pages
- 6 - 31
- publisher
- Rapid Communications
- external identifiers
-
- pmid:7749168
- scopus:0028899742
- ISSN
- 0959-4973
- language
- English
- LU publication?
- yes
- id
- 1198a2b7-4553-490c-a9f7-e02daeba7598
- alternative location
- https://journals.lww.com/anti-cancerdrugs/Abstract/1995/02001/Navoban___tropisetron__alone_and_in_combination.6.aspx
- date added to LUP
- 2019-09-20 08:07:23
- date last changed
- 2024-01-01 20:55:38
@article{1198a2b7-4553-490c-a9f7-e02daeba7598,
abstract = {{<p>To evaluate the efficacy and safety of Navoban (tropisetron) three different Nordic multicentre trials were conducted during the period 1988-92. In all, 1050 patients were recruited from 15 centres. In the first study, Navoban monotherapy was compared with a high-dose metoclopramide cocktail. In the second, Navoban +/- dexamethasone was evaluated for those patients not fully protected by Navoban alone. In the third trial, Navoban was evaluated for various chemotherapy regimens, for long-term efficacy, and for various risk groups of patients. Spontaneous intercycle variations were also evaluated. Navoban was found to be as effective as the antiemetic cocktail but with a more favourable spectrum of side effects and a simpler schedule of administration. Navoban was more effective during the acute than the delayed phase. Addition of dexamethasone significantly improved prevention of both acute and delayed emesis. Long term efficacy seemed to be stable up to 10 cycles of chemotherapy. Patients treated with noncisplatin regimens showed significantly higher protection rates than patients treated with cisplatin. Various cancer diagnoses and cytostatic agents were also evaluated. Gender and age were important risk factors. Navoban was found to be an efficacious antiemetic agent, especially regarding acute nausea and vomiting. Addition of a corticosteroid significantly improved the effect during highly emetogenic chemotherapy. The role of Navoban for delayed emesis must be evaluated in future trials. The two most common side effects were headache and constipation. Overall, Navoban was well tolerated and patient compliance with the drug was high.</p>}},
author = {{Sorbe, B G and Högberg, T and Glimelius, B and Schmidt, M and Wernstedt, L and Andersson, H and Hansen, O and Sørensen, B T and Räisänen, I}},
issn = {{0959-4973}},
keywords = {{Antiemetics/therapeutic use; Antineoplastic Agents/adverse effects; Dexamethasone/therapeutic use; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles/therapeutic use; Male; Nausea/chemically induced; Neoplasms/drug therapy; Risk Factors; Sweden; Tropisetron; Vomiting/chemically induced}},
language = {{eng}},
number = {{Suppl 1}},
pages = {{6--31}},
publisher = {{Rapid Communications}},
series = {{Anti-Cancer Drugs}},
title = {{Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting : the Nordic experience. The Nordic Antiemetic Trial Group}},
url = {{https://journals.lww.com/anti-cancerdrugs/Abstract/1995/02001/Navoban___tropisetron__alone_and_in_combination.6.aspx}},
volume = {{6}},
year = {{1995}},
}